JPS619A - 活性薬剤濃度分布が改良一定放出のためのシグモイダル濃度勾配を含む活性薬剤含有ヒドロゲルデバイス、その製造方法および使用 - Google Patents

活性薬剤濃度分布が改良一定放出のためのシグモイダル濃度勾配を含む活性薬剤含有ヒドロゲルデバイス、その製造方法および使用

Info

Publication number
JPS619A
JPS619A JP60098182A JP9818285A JPS619A JP S619 A JPS619 A JP S619A JP 60098182 A JP60098182 A JP 60098182A JP 9818285 A JP9818285 A JP 9818285A JP S619 A JPS619 A JP S619A
Authority
JP
Japan
Prior art keywords
active agent
hydrogel
bead
release
swollen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60098182A
Other languages
English (en)
Japanese (ja)
Inventor
ピン アイ.リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of JPS619A publication Critical patent/JPS619A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Colloid Chemistry (AREA)
JP60098182A 1984-05-10 1985-05-10 活性薬剤濃度分布が改良一定放出のためのシグモイダル濃度勾配を含む活性薬剤含有ヒドロゲルデバイス、その製造方法および使用 Pending JPS619A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US608756 1984-05-10

Publications (1)

Publication Number Publication Date
JPS619A true JPS619A (ja) 1986-01-06

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60098182A Pending JPS619A (ja) 1984-05-10 1985-05-10 活性薬剤濃度分布が改良一定放出のためのシグモイダル濃度勾配を含む活性薬剤含有ヒドロゲルデバイス、その製造方法および使用

Country Status (16)

Country Link
US (1) US4624848A (oth)
EP (1) EP0164311B1 (oth)
JP (1) JPS619A (oth)
AT (1) ATE61731T1 (oth)
AU (1) AU583507B2 (oth)
CA (1) CA1246447A (oth)
DE (1) DE3582193D1 (oth)
DK (1) DK205185A (oth)
ES (1) ES542948A0 (oth)
FI (1) FI851801L (oth)
GR (1) GR851114B (oth)
IL (1) IL75129A (oth)
NZ (1) NZ212030A (oth)
PH (1) PH24100A (oth)
PT (1) PT80416B (oth)
ZA (1) ZA853511B (oth)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784499A (en) * 1986-03-13 1988-11-15 Daido Metal Company Ltd. Bearing unit
JP2005507925A (ja) * 2001-10-29 2005-03-24 セリックス, インコーポレイテッド 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
EP0808153B1 (en) 1995-02-10 1999-08-04 Medtronic, Inc. Method and device for administering analgesics
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
CZ20022046A3 (cs) 1999-12-23 2002-11-13 Pfizer Products Inc. Hydrogelem hnaná dávková forma účinné sloľky
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ATE339170T1 (de) * 2001-07-23 2006-10-15 Alcon Inc Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
WO2003009774A2 (en) 2001-07-23 2003-02-06 Alcon, Inc. Ophthalmic drug delivery device
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
JP2007526019A (ja) * 2003-07-10 2007-09-13 アルコン,インコーポレイティド 眼科用薬物送達デバイス
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
EP1933852B1 (en) * 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CN106667918A (zh) 2005-11-28 2017-05-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
WO2008079440A2 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
AU2008299220B2 (en) 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2011505520A (ja) 2007-12-03 2011-02-24 メディパックス インコーポレイテッド 流体計量供給装置
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
EP2847249A4 (en) 2012-03-14 2016-12-28 Medipacs Inc Smart polymer materials with excess reactive molecules
MX348290B (es) 2012-06-04 2017-06-05 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
EP3838293A1 (en) 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
AU2013323206B2 (en) 2012-09-28 2017-07-20 Fred Hutchinson Cancer Center Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10399994B2 (en) 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
EA201792496A1 (ru) 2015-05-11 2018-04-30 Абиде Терапеутикс, Инк. Способы лечения воспаления или нейропатической боли
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
HK1257338A1 (zh) 2015-08-31 2019-10-18 Pharmacyclics Llc 用於治疗多发性骨髓瘤的btk抑制剂组合
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
CA3008289C (en) 2015-12-16 2023-10-31 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
US20190290650A1 (en) 2016-01-19 2019-09-26 Janssen Pharmaceutic Nv Formulations/compositions comprising a btk inhibitor
KR20180101521A (ko) 2016-01-19 2018-09-12 얀센 파마슈티카 엔.브이. Btk 저해제를 포함하는 제형/조성물
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN109310700A (zh) 2016-04-04 2019-02-05 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US11090702B2 (en) * 2016-06-28 2021-08-17 Trustees Of Tufts College Compositions and methods for delivery of active agents
PT3484862T (pt) 2016-07-18 2021-11-17 Arthrosi Therapeutics Inc Compostos, composições e métodos para o tratamento ou a prevenção de um sintoma associado a gota ou hiperuricemia
CN115215807A (zh) 2016-08-26 2022-10-21 科泰纳制药公司 Olig2活性的抑制
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
BR112019010003A2 (pt) 2016-11-16 2019-08-20 Abide Therapeutics Inc formas cristalinas de um inibidor de magl
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
US11779573B2 (en) 2017-09-01 2023-10-10 University Of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
KR20210073513A (ko) 2018-07-27 2021-06-18 컨센트릭 애널지식스, 인크. 페놀성 trpv1 작용제의 peg화된 프로드럭
US12419854B2 (en) 2018-12-06 2025-09-23 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
AU2019394974B2 (en) 2018-12-06 2025-08-28 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
SG11202109899VA (en) 2019-03-15 2021-10-28 Unicycive Therapeutics Inc Nicorandil derivatives
WO2021195425A1 (en) 2020-03-26 2021-09-30 Sinopia Biosciences, Inc. Isotopically-labelled trapidil derivatives
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
EP4149934A4 (en) 2020-05-11 2024-05-15 Cleave Therapeutics, Inc. CRYSTALLINE FORMS AND FORMULATIONS OF A VCP/P97 INHIBITOR
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
US20240190809A1 (en) 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
WO2022256720A2 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
EP4392028A4 (en) 2021-08-23 2025-09-24 Alexander Shulgin Res Institute Inc DEUTERATED EMPATHOGENS
CA3229910A1 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20240054333A (ko) 2021-08-31 2024-04-25 세레스파이어 인코포레이티드 공결정
IL311211A (en) 2021-09-03 2024-05-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
US12465578B2 (en) 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
EP4370506A1 (en) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CA3249142A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
CA3244485A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited BRIDGED CYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTS
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024011142A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
DE1617393C2 (de) * 1966-01-06 1982-11-11 Československá akademie věd, Praha Verfahren zur Herstellung von biologisch aktive Stoffe enthaltenden hydrophilen vernetzten Copolymeren
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
CA1125698A (en) * 1978-03-09 1982-06-15 Masaru Yoshida Process for preparing a polymer composition
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784499A (en) * 1986-03-13 1988-11-15 Daido Metal Company Ltd. Bearing unit
JP2005507925A (ja) * 2001-10-29 2005-03-24 セリックス, インコーポレイテッド 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム

Also Published As

Publication number Publication date
ATE61731T1 (de) 1991-04-15
FI851801A0 (fi) 1985-05-08
US4624848A (en) 1986-11-25
EP0164311B1 (en) 1991-03-20
PT80416B (en) 1987-04-16
FI851801A7 (fi) 1985-11-11
AU4221685A (en) 1985-11-14
ZA853511B (en) 1985-12-24
DE3582193D1 (de) 1991-04-25
CA1246447A (en) 1988-12-13
IL75129A (en) 1989-08-15
ES8603273A1 (es) 1986-01-01
GR851114B (oth) 1985-11-25
IL75129A0 (en) 1985-09-29
AU583507B2 (en) 1989-05-04
FI851801L (fi) 1985-11-11
NZ212030A (en) 1988-01-08
PH24100A (en) 1990-03-05
DK205185D0 (da) 1985-05-09
EP0164311A2 (en) 1985-12-11
ES542948A0 (es) 1986-01-01
DK205185A (da) 1985-11-11
PT80416A (en) 1985-06-01
EP0164311A3 (en) 1987-06-03

Similar Documents

Publication Publication Date Title
JPS619A (ja) 活性薬剤濃度分布が改良一定放出のためのシグモイダル濃度勾配を含む活性薬剤含有ヒドロゲルデバイス、その製造方法および使用
US4548990A (en) Crosslinked, porous polymers for controlled drug delivery
Huang et al. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems
Langer et al. Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review
US4749576A (en) Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
KR100314123B1 (ko) 경피투여시스템에적용가능한공중합체필름및그제조방법
US5580573A (en) Temperature activated controlled release
Dinerman et al. Solute diffusion in genetically engineered silk–elastinlike protein polymer hydrogels
US5750585A (en) Super absorbent hydrogel foams
US7988992B2 (en) Superporous hydrogels for heavy-duty applications
EP0250374B1 (en) Therapeutic system for controlled release of drugs
JPH03206030A (ja) 膨潤調節性ポリマードラツグデリバリー器具
NO311403B1 (no) Leveringsinnretning med innkapslede eksipienser og fremgangsmåte for avgivelse av et middel
NO843650L (no) Mikrofase-separerte hydrogeler for regulert frigivelse av bioaktive materialer
JPH0310667B2 (oth)
Ravichandran et al. Preparation, swelling characteristics and evaluation of hydrogels for stomach specific drug delivery
Reddy et al. Simultaneous and sequential micro-porous semi-interpenetrating polymer network hydrogel films for drug delivery and wound dressing applications
Sowjanya et al. Polymers used in the designing of controlled drug delivery system
Lowman et al. Structural and dynamic response of neutral and intelligent networks in biomedical environments
DK152831B (da) Fremgangsmaade ved fremstilling af biologisk aktive praeparater med reguleret afgivelse af aktivt stof samt polymerbaseret vaeskeformigt overtraekspraeparat til anvendelse ved fremgangsmaaden
Krajacic et al. Matrix formation in sustained release tablets: possible mechanism of dose dumping
Jenquin et al. Relationship of film properties to drug release from monolithic films containing adjuvants
MILLER et al. Diffusional release of water-soluble bioactive agents from ethylene-vinyl acetate copolymers
JPH0285216A (ja) 薬剤を制御して放出するための不均一な相互浸透ポリマー網状構造体
Ajaz et al. Development and evaluation of pH sensitive semi-interpenetrating networks: Assessing the impact of itaconic acid and aloe vera on network swelling and cetirizine release